Neoplasms, Endometrial: Clinical Trials

3 trials for Neoplasms, Endometrial, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Recruiting 1

Follow Neoplasms, Endometrial: new trials by email Literature Review of Neoplasms, Endometrial trials Research Report on Neoplasms, Endometrial

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Dostarlimab, Carboplatin, Paclitaxel - Neoplasms, Endometrial
Phase 2RecruitingGlaxoSmithKline302025-11-272025-12-22
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
pemetrexed - Neoplasms, Neoplasms by Site
Phase 2CompletedEli Lilly and Company272006-09-012009-11-20
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
topotecan - Neoplasms, Endometrial, Endometrial Cancer
Phase 2CompletedGlaxoSmithKline702005-10-012012-07-11

Narrower conditions

Endometrial Neoplasms (3)  ·  Genital Neoplasms, Female (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Urogenital Neoplasms (1)  ·  Uterine Neoplasms (1)

Broader conditions

Female Urogenital Diseases (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)  ·  Genital Diseases (3)  ·  Genital Diseases, Female (3)  ·  Urogenital Diseases (3)  ·  Uterine Diseases (3)  ·  Genital Neoplasms, Female (2)  ·  Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Urogenital Neoplasms (2)  ·  Uterine Neoplasms (2)  ·  Male Urogenital Diseases (1)

Interventions

Carboplatin (1)  ·  Paclitaxel (1)  ·  Pemetrexed (1)  ·  Topotecan (1)  ·  dostarlimab (1)

Sponsors

GlaxoSmithKline (2)  ·  Eli Lilly and Company (1)

Countries

United States (2)  ·  Canada (1)  ·  China (1)  ·  Hungary (1)

Top investigators

David Miller, MD (1)